home / stock / huma / huma articles
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repa...
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offer...
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday. Allakos Inc. ...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...